Glimepiride
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Glimepiride: From Type 2 Diabetes Mellitus to Focal Stiff Limb Syndrome
One-Sentence Summary
Glimepiride is a second-generation sulfonylurea, pharmacologically classified as an insulin secretagogue used to manage type 2 diabetes mellitus. The TxGNN model assigns a high prediction score to Focal Stiff Limb Syndrome, an autoimmune, GABAergic neurological disorder, but this direction is currently supported by 0 clinical trials and 0 publications, and the evidence pack explicitly flags the mechanistic link as unsupported.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 Diabetes Mellitus (based on known pharmacological classification as a sulfonylurea; no formal regulatory indication text available in this dataset) |
| Predicted New Indication | Focal Stiff Limb Syndrome |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for glimepiride was not directly available in the structured evidence pack (original_moa = Data Gap). However, based on known pharmacological classification, glimepiride is a second-generation sulfonylurea that binds SUR1 subunits to close ATP-sensitive K⁺ channels on pancreatic β-cells, promoting insulin secretion.
Focal Stiff Limb Syndrome (a localized variant of Stiff Person Syndrome) is an autoimmune neurological disorder driven by anti-GAD65 antibodies and impaired GABAergic neurotransmission. While ATP-sensitive K⁺ channels are also expressed in central neurons, there is currently no evidence that sulfonylurea-class drugs modulate GABAergic signaling or autoimmune GAD65-mediated pathology. The evidence pack itself characterizes this as a "high TxGNN score without a mechanistic basis" — i.e., the predicted link appears to be a graph-embedding artifact rather than a biologically grounded hypothesis.
Given the absence of mechanistic plausibility, clinical trial data, and literature support, this candidate should be interpreted as a low-confidence model output rather than a scientifically substantiated repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Germany Market Information
Glimepiride is not currently marketed in the jurisdiction covered by this regulatory dataset (market status: 未上市 / Not Marketed; 0 authorizations on record). No license or product information is available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Focal Stiff Limb Syndrome) carries an L5 evidence level — a TxGNN score with no supporting clinical trials, literature, or plausible mechanistic connection to glimepiride's known sulfonylurea pharmacology. Combined with the drug's non-marketed status in this jurisdiction and blocking safety data gaps, there is no basis to advance this candidate at this time.
To proceed, the following is needed:
- Confirmed drug label / warnings and contraindications from the local regulatory authority (currently a Blocking data gap — required before any S1 safety evaluation)
- Verified mechanism of action data from DrugBank or primary literature (High-severity data gap)
- Independent mechanistic or preclinical evidence linking sulfonylurea pharmacology to GABAergic/autoimmune neurological pathology, if this indication is to be pursued further
- Monitoring of lower-ranked candidates (e.g., thiamine-responsive dysfunction syndrome, rank 4) which show a somewhat more plausible — though still unverified — link to insulin secretion pathways, and may warrant a lower-priority literature search
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.